201. Novel thymohydroquinone gallate derivative loaded ligand modified quantum dots as pH-sensitive multi-modal theragnostic agent for cancer treatment.
- Author
-
Saeed U, Mahmood R, Fatima B, Hussain D, Liaqat S, Imran M, Ali Chohan T, Saqib Khan M, Akhter S, and Najam-Ul-Haq M
- Subjects
- Animals, Rats, Humans, Hydrogen-Ion Concentration, Benzoquinones chemistry, Benzoquinones administration & dosage, Benzoquinones pharmacology, Neoplasms drug therapy, Antineoplastic Agents pharmacology, Antineoplastic Agents administration & dosage, Antineoplastic Agents chemistry, Drug Carriers chemistry, Drug Liberation, Theranostic Nanomedicine methods, Cell Line, Tumor, Male, MCF-7 Cells, Nanoparticles chemistry, Cell Survival drug effects, Gallic Acid chemistry, Gallic Acid pharmacology, Quantum Dots chemistry
- Abstract
Background: Nanomedicine, as the combination of radiopharmaceutical and nanocarrier (QDs), is developed for treating cancer. Gallic acid is antimutagenic, anti-inflammatory, and anti-carcinogenic. Typical retention time of gallic acid is approximately 4 to 8 h. To increase the retention time gallic acid is converted to prodrug by adding lipophilic moieties, encapsulating in lipophilic nanoparticles, or liposome formation. Similarly, thymoquinone is powerful antioxidant, anti-apoptotic, and anti-inflammatory effect, with reduced DNA damage., Methods: In this study, a hydrophilic drug (gallic acid) is chemically linked to the hydrophobic drug (thymohydroquinone) to overcome the limitations of co-delivery of drugs. Thymohydroquinone (THQG) as the combination of gallic acid (GA) and thymoquinone (THQ) is loaded onto the PEI functionalized antimonene quantum dots (AM-QDs) and characterized by FTIR, UV-visible spectroscopy, X-ray powder diffraction, Zeta sizer, SEM and AFM, in-vitro and in-vivo assay, and hemolysis., Results: The calculated drug loading efficiency is 90 %. Drug release study suggests the drug combination is pH sensitive and it can encounters acidic pH, releasing the drug from the nanocarrier. The drug and drug-loaded nanocarrier possesses low cytotoxicity and cell viability on MCF-7 and Cal-27 cell lines. The proposed drug delivery system is radiolabeled with Iodine-131 (
131 I) and Technetium (99m Tc) and its deposition in various organs of rats' bodies is examined by SPECT-CT and gamma camera. Hemolytic activity of 2, 4, 6, and 8 μg/mL is 1.78, 4.16, 9.77, and 15.79 %, respectively, reflecting low levels of hemolysis. The system also sustains oxidative stress in cells and environment, decreasing ROS production to shield cells and keep them healthy., Conclusions: The results of this study suggest that the proposed drug carrier system can be used as a multi-modal theragnostic agent in cancer treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF